Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Dr Lim on the Potential Role for Subcutaneous Amivantamab in EGFR-Mutant NSCLC

September 9th 2025

Sun-Min Lim, MD, PhD, discusses the potential adoption of first-line subcutaneous amivantamab plus chemotherapy in EGFR-mutant NSCLC.

Dr Patel on Remaining Gaps in Biomarker Testing for Early-Stage Resected NSCLC

September 8th 2025

Sandip P. Patel, MD, discusses remaining gaps in biomarker testing and their implications for targeted therapies in early-stage NSCLC.

Dr Singhi on Responsibly and Effectively Leveraging Social Media for Patient Education in Oncology

September 8th 2025

Eric K. Singhi, MD, expands on how oncologists can work with patient advocacy groups on social media to improve patient education and engagement.

Final Analysis of Perioperative Tislelizumab Plus Chemotherapy Shows Sustained OS and EFS Improvement in Resectable NSCLC

September 8th 2025

Perioperative tislelizumab plus chemotherapy showed sustained OS and EFS improvement vs chemotherapy in resectable NSCLC.

Zidesamtinib Data Align With Clinical Expectations in Pretreated ROS1+ Advanced NSCLC

September 7th 2025

The brain-penetrant, TRK-sparing, ROS1-selective TKI zidesamtinib was active and safe in patients with advanced ROS1+ non–small cell lung cancer.

Ivonescimab Plus Chemo After Third-Generation TKI Generates Improved PFS in EGFR-Mutated NSCLC

September 7th 2025

Ivonescimab plus chemotherapy showed significant and clinically meaningful PFS in EGFR-mutated NSCLC following progression on a third-generation TKI.

Dr Liu on Updated Efficacy and Safety Data With Taletrectinib in ROS1+ NSCLC

September 7th 2025

Geoffrey Liu, MSc, MD, discusses updated efficacy and safety results with taletrectinib in ROS1-positive non–small cell lung cancer.

Dr Drilon on the Efficacy of Zidesamtinib Relative to Other ROS1 Inhibitors in Pretreated ROS1+ NSCLC

September 7th 2025

Alexander Drilon, MD, compares response rates with zidesamtinib with that of prior ROS1 inhibitors in pretreated patients with ROS1-positive NSCLC.

Mosunetuzumab Plus Polatuzumab Vedotin Triples Median PFS in Transplant-Ineligible LBCL

September 6th 2025

A chemotherapy-free regimen of mosunetuzumab and polatuzumab vedotin improved PFS and response rates vs R-GemOx in relapsed/refractory LBCL.

Off-the-Shelf, Fixed-Duration Combination Is Active in Relapsed/Refractory MCL

September 6th 2025

Treatment with mosunetuzumab plus polatuzumab vedotin yielded high response rates and had a manageable safety profile in BTK inhibitor–exposed MCL.

Orca-T Improves Moderate to Severe cGVHD-Free Survival in Hematologic Malignancies

September 5th 2025

Treatment with an investigational allogeneic T-cell immunotherapy improved outcomes vs conventional transplant in patients with hematologic malignancies

Dr Tashi on Differentiating Characteristics of Elenestinib in Indolent Systemic Mastocytosis

September 5th 2025

Tsewang Tashi, MD, discusses the aspects of elenestinib that differentiate it from avapritinib in the management of indolent systemic mastocytosis.

FDA Grants Fast Track Designation to CER-1236 in Acute Myeloid Leukemia

September 5th 2025

CER-1236 has received fast track designation from the FDA for the treatment of patients with acute myeloid leukemia.

Lunresertib and Other PKMYT1 Inhibitors Show Promise in Gynecologic Malignancies

September 5th 2025

Alison Schram, MD, discusses the potential clinical utility of PKMYT1-targeted agents in gynecologic malignancies.

Meta-Analysis Highlights Efficacy, Safety Benefits With Asciminib in Chronic Myeloid Leukemia

September 4th 2025

Findings from a meta-analysis associated asciminib with improved efficacy and safety vs other TKIs in chronic myeloid leukemia.

Zanubrutinib Prolongs PFS, Shows Trend Toward Improved OS in MAIC Analysis in CLL

September 4th 2025

Continuous zanubrutinib improved PFS and showed a trend for improved OS vs fixed-duration venetoclax-based therapy in treatment-naive CLL/SLL.

How Fellows Can Leverage Mentorship to Maximize Research Opportunities

September 2nd 2025

The director of the Hematology and Oncology Fellowship Program at Weill Cornell Medicine details how fellows can identify and maximize research opportunities.

Molecular Research With Benign, Self-Limiting Bone Lesion May Unlock New Treatment Avenues for RAS/MAPK-Activated Tumors

August 29th 2025

R. Lor Randall, MD, FACS, spreads awareness about the benign, self-correcting nature of non-ossifying fibromas, which are commonly confused with sarcoma.

Perioperative Tislelizumab Wins EU Approval for Resectable NSCLC at High Risk of Recurrence

August 27th 2025

The European Commission approved neoadjuvant tislelizumab plus chemotherapy, followed by adjuvant tislelizumab, for resectable non–small cell lung cancer.

Adjuvant Abemaciclib Plus Endocrine Therapy Improves OS in High-Risk HR+/HER2– Breast Cancer

August 27th 2025

The addition of abemaciclib to endocrine therapy after surgery improved OS in patients with HR-positive, HER2-negative breast cancer with positive nodes.